Oncolytics Biotech is a biotechnology company engaged in developing oncolytic viruses as potential therapeutics for cancer. Based in Calgary, Canada, the company has a clinical program that includes various human trials, such as a Phase III trial using REOLYSIN, its proprietary human reovirus formulation, in head and neck cancers. For more information, visit the company’s Web site at www.oncolyticsbiotech.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: